Single Ventricle Research Fund (SVRF) Grant

Single Ventricle Research Fund (SVRF) Grant

Status: ACTIVE
Funder: Additional Ventures Foundation
Amount: Up to US $600,000
Last Updated: November 09, 2025

Summary

The Single Ventricle Research Fund (SVRF) offers annual grants aimed at enhancing research and care for individuals with single ventricle heart defects. With awards of up to $600,000, the SVRF encourages innovative projects that align with the Additional Ventures Research Roadmap. This initiative not only supports novel treatments but also fosters collaboration across disciplines to address critical challenges in single ventricle heart disease management.

Overview

NOTE: If your team has a compelling topic to propose that is not currently represented in the Research Roadmap, we encourage you to contact our team and submit an LOI. Additional Ventures Mission Additional Ventures is a purpose-driven organization leveraging evidence-based research and deep subject matter expertise to make an outsized impact. Our relentless optimism powers bold, high-risk innovations to solve some of humanity’s most complex challenges. Single Ventricle Research Fund (SVRF) In its fourth cycle, the SVRF is hosting an open call, and welcomes any research with relevance to single ventricle. Resubmissions from previous cycles will also be accepted. What Fits Through the SVRF program, Additional Ventures aims to accelerate research that will lead to both improved care and novel treatments based on a mechanistic understanding of single ventricle. We have developed a Roadmap to Solving Single Ventricle Heart Disease in partnership with investigators across disciplines that identifies strategic solutions to address these gaps and challenges, which is intended to guide a decade’s worth of research efforts and serve as a framework for coordinating global resources to advance single ventricle research and clinical care. The SVRF welcomes research efforts relevant to single ventricle heart disease and aligned with any specific focus areas and areas of strategic investment in the Additional Ventures Research Roadmap, including genetics, basic cardiovascular development, tissue engineering, fetal and maternal health, computational modeling, and other relevant areas.

Eligibility

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.

Application Details

Additional Ventures 2026 Request for Proposals
Single Ventricle Research Fund
Letter of Intent Deadline: October 8, 2025
Invited Full Proposal Deadline: January 14, 2026

Table of Contents
2026 REQUEST FOR PROPOSALS ............................................................................................. 4
KEY DATES ............................................................................................................................. 4
DESCRIPTION ......................................................................................................................... 4
PROGRAM FOCUS .................................................................................................................. 5
ELIGIBILITY REQUIREMENTS ................................................................................................... 5
ADDITIONAL REVIEW CRITERIA .............................................................................................. 6
APPLICATION GUIDELINES ...................................................................................................... 7
LETTER OF INTENT ..........................................................................................................................7
FULL PROPOSAL ..............................................................................................................................8
COVID-19 & DISASTER POLICY, SUPPORT ....................................................................................... 10
REVIEW PROCESS ................................................................................................................. 10
REVIEWER RECOMMENDATIONS................................................................................................... 10
ACTIVITIES AND DELIVERABLES ............................................................................................ 11
TERMS OF GRANT / USE OF FUNDS ...................................................................................... 11
FUNDING AWARDED AT ADDITIONAL VENTURES’ DISCRETION ............................................. 11
QUESTIONS? ........................................................................................................................ 12
ABOUT ADDITIONAL VENTURES ........................................................................................... 12
Page 2 of 12

Single Ventricle Research Fund
The Single Ventricle Research Fund (SVRF) is an annual research award
program that supports foundational studies aimed at improving
outcomes for individuals with single ventricle heart disease.
(cid:56)(cid:73)(cid:66)(cid:85) (cid:39)(cid:74)(cid:85)(cid:84)
IMPORTANT DATES
All proposals must clearly link their aims, including work on the
Letter of Intent Due: origins or pathobiology of single ventricle heart disease, to
October 8, 2025 mechanisms driving long-term morbidity and mortality.
Invited Full Proposal Due:
o Priority outcomes include preventing or reversing key
(cid:43)(cid:66)nu(cid:66)r(cid:90) (cid:18)(cid:21), 2026
organ-level complications such as lymphatic
Award Announcements: dysfunction, liver disease, impaired kidney and gut
b(cid:90) June (cid:19)(cid:17), 2026 perfusion, heart failure, valve dysfunction, arrhythmia,
and neurodevelopmental challenges.
Anticipated Funding:
July 1, 2026
While these priority areas reflect the most pressing outcome-related
challenges in single ventricle heart disease, the SVRF remains open to
bold, innovative proposals that may emerge outside of these focus areas.
S(cid:55)R(cid:39) IN(cid:55)ESTMENT SIN(cid:36)E
(cid:19)(cid:17)(cid:19)(cid:17)
Wh(cid:66)(cid:85) (cid:69)(cid:80)(cid:70)(cid:84) N(cid:80)(cid:85) (cid:71)(cid:74)(cid:85)
Cumulative Investment:
$48M (cid:36)linic(cid:66)l tri(cid:66)l(cid:84)(cid:13) (cid:81)urel(cid:90) tr(cid:66)n(cid:84)l(cid:66)tion(cid:66)l projects(cid:13) (cid:81)rotot(cid:90)(cid:81)in(cid:72)(cid:13) dru(cid:72)
develo(cid:81)(cid:78)ent. Projects focused solely on cardiac development or
(cid:41)i(cid:84)toric (cid:34)(cid:88)(cid:66)rd (cid:51)(cid:66)te(cid:27)
malformations without outcome relevance will not be considered.
(cid:95)(cid:18)(cid:17)(cid:6)
P(cid:83)(cid:80)(cid:72)(cid:83)(cid:66)(cid:78) T(cid:83)(cid:66)(cid:68)(cid:76)(cid:84) (cid:66)(cid:79)(cid:69) E(cid:77)(cid:74)(cid:72)(cid:74)(cid:67)(cid:74)(cid:77)(cid:74)(cid:85)(cid:90)
(cid:42)ndependent (cid:42)nvestigator Track
(cid:54)p to (cid:5)(cid:23)(cid:17)(cid:17),(cid:17)(cid:17)(cid:17) in direct costs and (cid:5)(cid:23)(cid:17),(cid:17)(cid:17)(cid:17) in indirect costs.
(cid:48)pen to (cid:42)ndependent investigators of all levels.
(cid:36)areer (cid:37)evelopment Track
(cid:54)p to (cid:5)(cid:20)(cid:17)(cid:17),(cid:17)(cid:17)(cid:17) in direct costs and (cid:5)(cid:20)(cid:17),(cid:17)(cid:17)(cid:17) in indirect costs.
(cid:48)pen to applicants in mentored research training positions.
Questions?
Contact grants@additionalventures.org
Visit www.additionalventures.org for more information

2026 REQUEST FOR PROPOSALS
The Single Ventricle Research Fund (SVRF) is an annual research award program that supports foundational studies
aimed at improving outcomes for individuals with single ventricle heart disease. By addressing the organ and multi-
organ-level complications and clinical sequelae that drive long-term morbidity and mortality, the SVRF seeks to close
critical gaps in understanding and treatment and accelerate progress toward better, more predictive, and
preventative care.
A program of Additional Ventures—a nonprofit foundation dedicated to curing single ventricle heart disease—the
SVRF offers multi-year, high-impact grants through two tracks: the Independent Investigator Track (up to $600,000
in direct costs over three years) and the Career Development Track (up to $300,000 in direct costs over three years).
In its sixth cycle, the SVRF welcomes foundational research that is directly relevant to improving outcomes for
individuals with single ventricle heart disease. All proposals must clearly demonstrate how their aims—including any
work on the origins or pathobiology of single ventricle heart disease—relate to the mechanisms driving long-term
morbidity and mortality. Studies that examine cardiac development or the causes of single ventricle malformations
without clear links to patient outcomes will not be considered.
Priority outcomes include the prevention or reversal of interrelated organ-level sequelae such as lymphatic
dysfunction, liver disease, impaired kidney and gut perfusion, heart failure and valve dysfunction, arrhythmia, and
neurodevelopmental challenges. The program particularly encourages foundational science that could lead to
targeted interventions addressing these complications and improving quality of life and survival. Resubmissions from
previous cycles will be accepted.
While these priority areas reflect the most pressing outcome-related challenges in single ventricle heart disease, the
SVRF remains open to bold, innovative proposals that may emerge outside of these focus areas. Applications that
introduce novel concepts or unexpected avenues for improving outcomes are encouraged, provided they maintain
clear relevance to the long-term health and quality of life of individuals with single ventricle heart defects.
This award exclusively supports foundational basic and clinical research projects that aim to improve our
understanding of single ventricle heart disease. Registry and biorepository builds will not be considered. Purely
translational research, including prototype and therapeutic development, will be redirected to Additional Ventures’
new Translational Accelerator Program.
KEY DATES
Letter of Intent Due October 8, 2025, 5 pm PST
Invitation to Submit Full Proposal November 13, 2025
Full Proposal Due January 14, 2026, 5 pm PST
Awardees Announced by June 20, 2026
Award Begins July 1, 2026
DESCRIPTION
The SVRF supports foundational research efforts aimed at advancing the understanding of and treatment paradigms
for single ventricle heart disease. Historically, award cycles have selected 14-17 proposals each year and have
collectively awarded over $48M to support SV research. We reserve the right to fund any number of grants based
on the quality, number, and diversity of applications received.
Each grant will provide funding to be utilized over three (3) years to support research projects led by doctoral-level
investigators (e.g., PhD, MD, PsyD) at qualifying research-based institutions. Indirect costs up to 10% will be provided
in addition to the total direct costs (please consult our policy for more information).
Page 4 of 12

See below for details on the application and review processes.
PROGRAM FOCUS
Through the SVRF program, Additional Ventures aims to accelerate foundational research that will lead to both
improved care and novel treatments based on a mechanistic understanding of single ventricle. We are particularly
interested in proposals that seek to prevent and reverse the interrelated organ-level sequelae that contribute to
long-term morbidity and mortality. This includes advancing lymphatic restoration, liver health, kidney and gut
perfusion, arrhythmia mitigation, cardiac integrity and failure, and neurodevelopmental outcomes. By pursuing
scalable and biologically informed strategies across these domains, we aim to preserve organ function, reduce
secondary complications, and improve outcomes and quality of life for individuals living with single ventricle heart
defects.
Through the SVRF program, Additional Ventures is committed to advancing foundational research that drives
meaningful improvements in outcomes for people living with single ventricle heart disease. While we recognize that
understanding mechanisms, including pathobiology and disease origins, can inform innovation, all supported work
must clearly connect these insights to the complications and sequelae that shape long-term survival and quality of
life.
The program prioritizes research that addresses the interconnected organ-level challenges of single ventricle
disease—such as lymphatic dysfunction, liver injury, kidney and gut perfusion deficits, arrhythmias, valve
dysfunction, heart failure, and neurodevelopmental impairments. By fostering biologically grounded and scalable
approaches in these areas, the SVRF aims to reduce secondary complications, preserve multi-organ health, and
accelerate progress toward transformative treatments and care strategies.
While these priority areas reflect the most pressing outcome-related challenges in single ventricle heart disease, the
SVRF remains open to bold, innovative proposals that may emerge outside of these focus areas. Applications that
introduce novel concepts or unexpected avenues for improving outcomes are encouraged, provided they maintain
clear relevance to the long-term health and quality of life of individuals with single ventricle heart defects.
For more information, visit our website.
ELIGIBILITY REQUIREMENTS
1. Proposed projects must be led by principal investigator(s) (PIs) who hold doctoral degrees (e.g. PhD, MD,
PsyD, or equivalent doctorates).
a. SVRF Independent Investigator Track: Open to independent investigators of all levels, including
those with Instructor or Assistant Professor status, and non-tenure track or research faculty.
i. In the instance where a project is collaborative in nature (i.e., includes multiple lead
investigators who make significant contributions), one Principal Investigator must be
selected. Additional lead investigators should be listed as Co-Investigators (maximum of
5). The selected Principal Investigator will be the primary contact during the course of
application and through post-award management (if awarded), including contracting and
progress reporting. All PIs and Co-Investigators must meet eligibility criteria.
b. SVRF Career Development Track: Open to early career applicants in mentored (non-independent)
research training positions such as a postdoctoral fellowship and within ten (10) years of the
conferral date of their terminal doctoral degree relative to the SVRF LOI due date.
i. Exceptions to this timeline include, and are not limited to: 1) childbirth or adoption (one
(1) year automatic extension), 2) extenuating circumstances related to child, elder, or
Page 5 of 12

family care, 3) periods of part-time work or leave, 4) period of time after receipt of
terminal degree requirements when the investigator was not conducting research
(including required clinical training/activities, or time away due to medical issues, military
service, natural disasters, or family care), and 4) significant change in field of study.
Contact Additional Ventures for more information.
ii. Independent investigators serving in an advisory or mentor capacity may be included as
Co-Investigators (maximum of 5).
iii. If an awardee obtains independent research status (e.g., secures an independent faculty
position, or equivalent) at any point between the LOI submission and the notification of
the funding decision or activation of the award, they must communicate this to Additional
Ventures.
2. All applicants must be affiliated with a nonprofit academic or research institution, including domestic and
non-US nonprofit organizations, domestic and non-US public/private academic universities or institutions
of higher learning (including colleges, universities, medical schools, and other related academic research
institutions); certain qualified governmental agencies with active biomedical research programs may also
apply.
3. Proposed research must focus on defined topics outlined above; biorepository and registry builds will not
be considered. Proposals focused exclusively on the development of prototypes and therapeutics will not
be considered, unless the work is proposed as a sub-Aim or component of a proposal with a primary focus
on mechanisms of disease; these proposals may be eligible for funding through an alternate Additional
Ventures funding mechanism (see our website for updates and application timelines).
4. Additional Ventures generally welcomes grant applications from scientists and researchers worldwide.
However, as a U.S.-based organization, it is subject to U.S. laws and regulations and must operate in full
compliance with them. Accordingly, Additional Ventures is prohibited from awarding, and will not award,
grants that would violate any applicable U.S. statute, regulation, or executive order. This includes, but is
not limited to, restrictions that prevent funding to: (i) any individual or entity subject to comprehensive or
targeted U.S. sanctions, including where such funding would result in a violation of those sanctions; (ii) any
individual or entity identified on the U.S. Department of the Treasury’s Specially Designated Nationals and
Blocked Persons List (SDN List), or any entity owned or controlled by such persons; or (iii) any individual or
entity where providing such funding would otherwise contravene U.S. laws relating to anti-terrorism or
national security.
ADDITIONAL REVIEW CRITERIA
When evaluating the overall impact of submissions, Additional Ventures may consider the following:
 Collaborative projects led by PIs across multiple institutions, disciplines, or scientific arc (e.g. collaboration
between clinical and basic research scientists)
 Proposals led by women and underrepresented minorities
 Proposals from investigators new to SV and associated conditions
o For the purposes of this RFP, “new to SV and its associated conditions” identifies a principal
investigator who has not authored a publication relating to SV and its associated conditions and
has not been the PI on a grant related to SV and its associated conditions awarded from a grant-
making agency, non-profit, foundation, or other grant-awarding organization.
 Proposals from early career investigators
o For purposes of this RFP, an independent “early career investigator” is an individual who has had
an independent lab or clinical research position for no longer than seven (7) years past their post-
doctoral position or medical fellow position OR is currently in a mentored training position and
Page 6 of 12

meets eligibility criteria for the SVRF Career Development Track. If an investigator has achieved
independence directly following graduate school, “early career investigator” status applies if an
independent research position has been held for ten (10) years or less.
o Applications to the SVRF Career Development Track from mentored early career investigators will
be reviewed separately from applications received from independent investigators.
Applicants are not required to provide demographic information. Responses will be visible only to Additional
Ventures; outside reviewers will not have access to this information.
APPLICATION GUIDELINES
All applicants will submit their completed LOI and Full Proposal application materials through the Additional
Ventures online grant portal (see below for submission details). All application materials should be single-spaced
and formatted in a sans-serif, 11-point font with 0.5-inch (or larger) margins as a PDF file, except where provided
templates or fillable forms apply.
Please visit the application portal for the most up-to-date information and log in to start your application. Login to
ProposalCentral by visiting www.proposalcentral.com and select the Single Ventricle Research Fund in the Grant
Opportunities tab, or access the portal via this direct link. To revisit an application already in progress, select your
draft under the Proposals tab.
Applicants will first submit an LOI; full proposal submissions are by invitation only. LOIs will be evaluated for
completeness, competitiveness, responsiveness to the call, portfolio impact, and potential impact of the work to
further knowledge and mechanistic understanding of single ventricle and/or treatment options and outcomes.
LETTER OF INTENT
LOIs will be submitted through the online grant portal. The LOI will require the applicant organization’s legal name,
PI name, degree, position, and contact information. If the proposal is a collaboration, information including the co-
investigator(s) name, degree, position, and organization will also be collected.
 LOIs are due on October 8th, 2025 by 5 pm PT.
 On the Title Page within Proposal Central, select the appropriate Program Track (see Eligibility).
 Within the portal, information about the applicant team and associated institute(s) will be collected,
including financial and signing official contact information.
 Applicants will be asked to provide a selection of keywords relevant to the project and to categorize their
proposed work along several pre-defined axes.
 The LOI includes responses to the following prompts (submitted within ProposalCentral):
o Project Summary (500 characters maximum)
▪ Provide a lay summary of your proposed research project.
o Scientific Goals & Strategy (2500 characters maximum)
▪ Describe the central question that your project seeks to address and the methods that
will be used to interrogate your hypotheses. Describe whole-animal models, primary
human datasets, and/or primary human experimental paradigms you will use and what
features you will measure. Provide information (references, rationale, or preliminary
data) to justify your selected experimental model(s)/paradigm(s). Describe research tool
and model (animal, IPSC, human tissue, etc.) availability and status (e.g., source, breeding
programs, tool compounds, viral vector generation). If using genetic methods, indicate
the approach (e.g., siRNA, viral vector overexpression, knockdown). If using single cell
analyses, indicate type and rationale for use (e.g., snRNAseq, ATACseq, etc.). If using
Page 7 of 12

pharmacological methods, provide information on the intended molecular target and
readout to indicate the ability of the compound to reach and engage the target in vivo.
o Statement of Impact and Alignment with SVRF Focus (500 characters maximum)
▪ Explain how the proposed work will advance our treatment or mechanistic understanding
of single ventricle congenital heart disease (including but not limited to: disease etiology,
outcomes, treatment of comorbidities and complications, and/or cures). Describe what
unique value your proposed research will add to the field that does not already exist, and
further, how this proposed research aligns with the goals and scientific focus areas
outlined in this RFP.
 Applicants will be notified via email by November 13, 2025 if they have been invited to submit a full
proposal.
FULL PROPOSAL
If invited, a formal proposal outlining the intended project should be submitted to Additional Ventures by January
14, 2026, 5 pm PT, via the online application portal. The proposal must contain the following elements, following
appropriate formatting guidelines, entered into the grant portal fillable forms, or using downloadable templates
(available within the portal) where applicable. Required elements should not exceed the page or character limit,
where applicable. Detailed application instructions will be made available to invited applicants within the portal, and
will include the following major elements:
 Title Page
 Principal Investigator
o Including PI name, institution, degree(s), academic rank, and contact information
o PI biosketch
 Institution information
 Key Personnel
o Including co-investigator, collaborator, or contractor name, institution, degree(s), academic rank,
and contact information
o Co-investigator biosketch (not required for other personnel)
 Project Summary
o Lay summary (written for the general public) describing the project’s aims and goals, including
how the completion of the study will impact single ventricle research and/or care (up to 2100
characters)
o Technical abstract (up to 2100 characters)
 Team and Community
o Team Contributions (up to 6000 characters)
▪ List the key personnel associated with your project (including open roles to be filled if
the project is funded) and provide 1-3 sentences for each individual/role describing their
expertise/expected contributions. If students and postdocs comprise a portion of the
research team, describe how their involvement will support their future career goals.
▪ SVRF Career Development applicants may use additional space (up to 6000 characters
total) to describe the role of their mentor(s) and/or advisors(s) in both the execution of
the project and their anticipated career development.
Page 8 of 12

o Community Participation and Engagement (check box to acknowledge)
▪ Applicants will acknowledge that Additional Ventures requires as a condition of funding
that SVRF research teams attend and participate in Additional Ventures-led activities,
including our biennial Single Ventricle Investigator Meeting (October 2026; October
2028), progress report virtual meetings (Q2 of each funded year), and virtual Additional
Ventures Speaker Series or other community programming held throughout the year.
o Data Sharing Plan and Philosophy (check box to acknowledge)
▪ Applicants will agree to comply with Additional Ventures’ open data-sharing policy as
outlined in the Additional Ventures Terms & Conditions.
 Detailed Budget (fillable form)
o A detailed budget in USD completed within the portal.
o Acceptable expenditures include but are not limited to: salary (must adhere to current NIH cap),
equipment, reagents, graduate student tuition, software, patient recruitment, fringe benefits,
project-related or conference travel, publication costs, and up to 10% indirect costs in addition to
the awarded amount (e.g. $60,000 in addition to an award of $600,000). See here for our
institutional policy.
o If more than one institution will be involved in the project, one should be proposed as the
applicant organization, and the other(s) included as a sub-grantee.
o For non-US applicants: All grants will be made in USD, and SVRF is not responsible for any
changes in conversion rates. Grants selected for funding will be made payable to the applicant
organization; under no circumstances will payment be made to an individual.
 Budget Summary (up to 4000 characters)
o Provide justification of key budget items, specifying their relevance to the project and an
estimate of the total costs/budget percentage associated with each proposed Aim.
o If the application includes subcontracts, provide a brief description of the contributions of the
subcontracted team/services, and list the total amount to be paid per budget period (direct and
indirect costs listed separately).
 Uploaded Documents (all to be included in PDF format):
o Specific Aims page: a brief yet technical summary of the project’s scientific goals and expected
products (e.g. publications, protocols, databases). One (1) page. Figures are permitted.
o Major milestones (including Aims) should include estimated timeline to completion.
▪ Track-specific templates are available within the grant portal.
o Scientific Approach
▪ Outline of research methodology to be used in pursuit of the project, including
discussion of expected results, statistical analysis of data (where appropriate), and
possible alternative approaches. Figures are permitted.
• Independent track applicants must adhere to six (6) pages or fewer.
• Career Development SVRF applicants are limited to four (4) pages or fewer.
o Clinical, Human, or Animal Protocol Synopsis (if applicable)
▪ Proposals for clinical, basic human, or animal studies are welcome and must be
accompanied by a brief protocol synopsis and timeline with milestones. IRB (for human
studies) or IACUC (for animal studies) approval will be required before initial payments
Page 9 of 12

are made for any project that SVRF, at its sole discretion, selects for funding. If
applicable, two (2) pages or fewer.
o References cited; no strict page limit; submitted in PDF format.
o Letters of support from additional collaborators or other sources, if applicable.
o Resubmission Revision Statement (required for Resubmissions):
▪ Applicants submitting applications that had been evaluated in prior award cycles are
required to submit a one (1)-page document outlining the revisions made to their
application since their last submission. Describe any new data, changes to approaches
or techniques, and any other updates.
COVID-19 & DISASTER POLICY, SUPPORT
As a foundation, Additional Ventures is deeply committed to supporting our scientific communities. We are sensitive
to how COVID-19 and other disasters may affect the wellbeing of our grantees, and are dedicated to supporting
scientists, clinicians, and academics through unprecedented times and experiences.
We anticipate that COVID-19, global disasters, and other unforeseen challenges will cause delays and changes to
planned research activities, through the introduction of both professional and personal difficulties. The Additional
Ventures team is cognizant that no standard plan will work for all grantees or apply to all situations; as such, we are
willing to work with our grantees on a personal basis to discuss options and find appropriate solutions. These may
include, and are not limited to: budgeting revisions, revisions to timelines and due dates of deliverables, personnel
changes, and allowances for child/dependent care or transportation. Please contact our team to discuss how we can
help; we know that allowing flexibility means a greater chance of success.
REVIEW PROCESS
The Single Ventricle Research Fund utilizes a two-step review process. First, LOIs are reviewed to assess eligibility
and fit within the scientific focus and scope of the grant program. LOI submissions are evaluated by internal
reviewers, and decisions will be communicated November 13th, 2025. Selected investigators will be invited to submit
full proposals that will be reviewed by external committees, described below.
Upon LOI assessment and invitation to submit full proposals, Additional Ventures forms review committees
comprised of independent expert reviewers to accommodate the specific expertise required each year. External
review committees evaluate full-length proposals based on scientific and technical merit, team capabilities and
competencies, realism of cost, and the commitment to the scientific community. Independent Investigator and
Career Development Track submissions are evaluated separately. While reviewers make recommendations to
Additional Ventures for funding, all decisions are at the sole discretion of Additional Ventures. Decisions will be
communicated by June 20th, 2026.
Additional Ventures will provide feedback for all proposals not selected for funding. Receipt of feedback is an
important part of the scientific process, and we provide written critiques and comments as submitted by external
reviewers for all applicants. While these evaluations constitute a critical element of our review process, please note
that they may not reflect all aspects of decision-making. We often solicit further input on proposals from reviewers
in discussion or from additional evaluators (particularly in cases of disagreement or bias) that occur beyond the
scope of these written comments.
REVIEWER RECOMMENDATIONS
Upon invitation to submit full proposals, applicants are invited to submit reviewer preferences via Proposal Central
by December 6th, 2025 (1 month prior to the Full Proposal due date). Applicants may list suggested scientific peers
who would provide a fair and equitable review of the proposal and who are well-matched with respect to expertise,
Page 10 of 12

or to list those to exclude from consideration. Each applicant may list up to three individuals in each category.
Submitting reviewer recommendations does not guarantee inclusion or exclusion of the listed reviewers. Scientific
review is blinded to applicants and is assigned and managed at the discretion of Additional Ventures only.
ACTIVITIES AND DELIVERABLES
Grantees funded by this effort will be expected to engage in the activities and provide deliverables described below:
 Annual progress reporting, including updates given via teleconference, presentations at virtual meetings,
and/or written reports. Regardless of format, progress reports may include the following:
o Description of scientific progress towards project goals,
o Annual description of milestones achieved or postponed,
o Annual budget update and expenditure report,
o A report of annual participation in community, leadership, and mentoring activities (template
provided).
 Attendance at the biennial Additional Ventures Single Ventricle Investigator Meeting (SVIM); presentations
at SVIM are encouraged to be made by postdoctoral research associates or pre-doctoral students on behalf
of the research team.
 Active participation in Additional Ventures-led meetings or workshops that bring together grantees to share
progress and results, or to promote leadership, professional, or community enrichment.
 Response to reporting inquiries requested by Additional Ventures, relating and not limited to: publications
and presentations, patents, collaborations, external award of additional funding, students, and
postdoctoral associates trained in association with work funded by Additional Ventures.
SVRF Career Development awardees may be offered additional support throughout the duration of their award
period, including career training, mentorship activities, and workshops, and are invited to attend and participate in
monthly meetings with Additional Ventures early career awardees. These activities are not required.
TERMS OF GRANT / USE OF FUNDS
Each funded organization will be required to sign and agree to the SVRF’s grant terms within thirty (30) days from
receipt of notice of the award and prior to the funds being released. The grant terms will be available upon
submission of a full proposal. Please note that Additional Ventures does not modify award agreement terms for
individual institutions; see our Terms & Conditions. Terms must be agreed to by the applicant’s host institution in
full without modification.
FUNDING AWARDED AT ADDITIONAL VENTURES’ DISCRETION
Responding to this RFP, submitting an LOI and/or submitting a full proposal does not entitle any individual or
institution to receive funding from Additional Ventures. Funding, if any, would be provided at Additional Ventures’
sole discretion pursuant to the terms of a written grant agreement executed by Additional Ventures and the selected
grantee organization, the terms of which Additional Ventures may require to be acknowledged by the PI.
Financial Responsibility: Funding is awarded to the institution and/or organization, not to the individual principal
investigator. The principal investigator or a first-degree relative cannot be listed as the signing official or financial
officer, or have checks sent to their attention if awarded.
Page 11 of 12

NONDISCRIMINATION AND HARASSMENT STATEMENT:
Additional Ventures is committed to providing an environment free from harassment and discrimination.
Additional Ventures prohibits harassment and discrimination based on race; creed; color; religion; sex; sexual
orientation; national origin; ancestry; age; Veteran status; citizenship status; marital status; physical or mental
disabilities; pregnancy, gender identity or expression (including transgender status); genetic information; and any
other characteristic protected by federal, state, or local law.
QUESTIONS?
For all inquiries, please contact our team at grants@additionalventures.org.
ABOUT ADDITIONAL VENTURES
Additional Ventures is a nonprofit foundation that aims to accelerate research progress and improve clinical care
for children born with complex congenital heart defects so that they have a normal duration and quality of life.
Although one in one hundred children are born with a congenital heart defect, there are limited options for those
with the most complex forms, including single ventricle (SV) heart defects. For these children, there is no cure.
With rapid advances in areas like genomics, single-cell technologies, and tissue engineering, now is the time to
coordinate concerted efforts to understand how to overcome this devastating, complex disease.
Page 12 of 12